{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-021461","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.222623+00:00","generated_at":"2026-06-04T23:45:07.771203+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"OptimizeRx reaffirms FY2023 prelim revenue >$68-70M; updates 2024 revenue guidance to at least $100M","bullets":["FY2023 preliminary revenue exceeds $68-70M range; adjusted EBITDA in $3-4M range, consistent with prior guidance.","2024 revenue guidance revised to at least $100M due to gross-to-net revenue recognition change for Medicx Health.","2024 adjusted EBITDA guidance unchanged at greater than $11M.","FY2023 earnings call scheduled for March 28, 2024; year-end audit ongoing including Medicx Health and material weakness remediation."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-021461","json":"https://secwatch.observer/filing/0001213900-24-021461.json","markdown":"https://secwatch.observer/filing/0001213900-24-021461.md","text":"https://secwatch.observer/filing/0001213900-24-021461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024021461/0001213900-24-021461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024021461/ea0201581-8k_optimize.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:45:07.771203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f78a5166d7c1413dfd3c751d4bfadb1a0067bc8d","claim":"OptimizeRx Corp reported FY2023 results: revenue $68-$70 million. Guidance reaffirmed.","evidence_excerpt":"EBITDA guidance remains unchanged, at greater than $11 million for 2024. Based on its preliminary, unaudited review, OptimizeRx estimates FY2023 revenue to exceed the range of $68-$70 million and adjusted EBITDA to be in the range of $3-$4 million, which is consistent with the Company’s previously announced guidance. The estimated revenue and adjusted","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024021461/0001213900-24-021461-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY2023"},{"label":"Revenue","value":"$68-$70 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}